Skip to main content

Clinical Trials Using Therapeutic Allogeneic Lymphocytes

Review the clinical trials studying therapeutic allogeneic lymphocytes on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 108

Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Haploidentical Viral-Specific T-Cells for Treatment of Patients with Refractory Cytomegalovirus and/or Adenovirus Infections after Hematopoietic Cell Transplantation
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 2 locations
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) cells with or without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Universal Donor Natural Killer Cells for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, KARMA Trial
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
CD70 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Engineered Cells (TGFBR2 KO CAR27/IL-15 NK cells) for the Treatment of Relapsed or Refractory Myeloid Malignancies
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Engineered Cells (NY-ESO-1 TCR/IL-15 NK cells) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Engineered Cells (UCD19 CAR-T Cells) for the Treatment of Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia or B-cell Non-Hodgkin Lymphoma
Status: Active
Location: Children's Hospital Colorado, Aurora, Colorado
iC9 CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Relapsed or Refractory T-cell Leukemia or Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
TGFbeta-imprinted Natural Killer Cells in Combination with Irinotecan, Temozolomide, and Dinutuximab for the Treatment of Patients with Relapsed or Refractory Neuroblastoma, Allo-STING Trial
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Modified Memory-Like NK Cells and TCRαβ T-cell Depleted Half-Matched Related Donor Transplant for the Treatment of High-Risk Acute Myeloid Leukemia (ABCD NK trial)
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Status: Active
Location: 2 locations
Allogeneic Virus-Specific T-lymphocyte Infusion for the Treatment of Patients with Epstein-Barr Virus, Cytomegalovirus, Adenovirus, or BK Virus Infection
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Donor T Cell Therapy in Treating Immunocompromised Patients with Adenovirus-Related Disease
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Grade 4 Recurrent Astrocytoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
A Phase 1 Study of ADI-001 in Autoimmune Disease
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Donor Immune Cells (TGFBi NK cells) for the Treatment of Recurrent, Progressive or Refractory Malignant Brain Tumors in Children and Young Adults
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients with Chronic Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Intraperitoneal FT536 with Lymphodepleting Chemotherapy for the Treatment of Patients with Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland